Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight-loss drugs Ozempic and ...

Eli Lilly plans to make its experimental drug orforglipron in the U.S. after it secures regulatory approval, says CEO Dave ...

The drug reduced weight by 16 pounds, on average, at the highest dose The pill could make treatment easier for people who don’t want to inject themselves You must be logged in to rate. Click any ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

A DAILY weight loss pill that works like Ozempic has succeeded in a major clinical trial. Patients lost an average of a stone and two pounds (7.3kg) each over 10 months. Unhealthy blood sugar ...

Eli Lilly said its drugs showed no signs of live injury in the trial. This is welcome news for researchers after Pfizer ...

In a new First Opinion essay, Borio and Krause, both once top FDA officials, say the commissioner made a “rookie misstep” in ...

Continue » The leader in diabetes and obesity Despite Lilly's huge success in treating diabetes and obesity, it's not the ...

Eli Lilly’s new obesity and diabetes pill has shown it can lower blood sugar and aid weight loss in a late-stage trial, ...